Caterina Fumagalli

Dr. Caterina Fumagalli

European Institute of Oncology IRCCS
orcid

Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 May 2015 in European Radiology
Verified
Journal Article
Closed access
PDF file
SRStefania Rizzo
Stefania Rizzo
Francesco PetrellaFrancesco Petrella
Francesco Petrella
VBValentina Buscarino
Valentina Buscarino
FMFederica De Maria
Federica De Maria
SRSara Raimondi
Sara Raimondi
MBMassimo Bellomi
Massimo Bellomi

4 January 2009 in International Journal of Surgical Pathology
Verified
Journal Article
Closed access
PDF file
GPGiuseppe Pelosi
Giuseppe Pelosi
ASAngelica Sonzogni
Angelica Sonzogni
TPTommaso De Pas
Tommaso De Pas
DGDomenico Galetta
Domenico Galetta
GVGiulia Veronesi
Giulia Veronesi
JRJuan Rosai
Juan Rosai
Pulmonary sarcomatoid carcinomas (PSCs) are currently defined as poorly differentiated non-small-cell carcinomas containing a component with sarcoma or sarcoma-like (spindle and/or giant cell) features. They consist of 5 major histological variants, namely pleomorphic carcinoma, spindle cell carcinoma, giant cell carcinoma, carcinosarcoma, and pulmonary blastoma. The segregation of PSCs into a distinct clinicopathologic entity seems justified on the basis of morphologic, behavioral, and genotypic/phenotypic attributes. As a group, PSCs generally run an aggressive clinical course and may cause major difficulties in the differential diagnosis with other primary and secondary malignancies of the lung. At present, PSCs are believed to represent a family of carcinomas “in transition,” in which diverse pathways of clonal evolution account for histological differences of a common ancestor lesion. The sarcomatous or sarcomatoid component of these tumors is thought to derive from carcinoma cells during the progression of carcinogenesis through the activation of an epithelial—mesenchymal transition program leading to sarcomatous transformation or metaplasia (conversion paradigm). Conceivably, targeting the epithelial—mesenchymal transition program could become a valid therapeutic strategy for these life-threatening tumors, whose sensitivity to current medical manipulation is disappointing.

1 November 2011 in Journal of Thoracic Oncology
Verified
Journal Article
Closed access
PDF file
TPTommaso De Pas
Tommaso De Pas
FTFrancesca Toffalorio
Francesca Toffalorio
MMMichela Manzotti
Michela Manzotti
CFCaterina Fumagalli
Caterina Fumagalli
GSGianluca Spitaleri
Gianluca Spitaleri
MBMassimo Barberis
Massimo Barberis

27 August 2021 in Diagnostics
Verified
Journal Article
Open access
PDF file
CFCaterina Fumagalli
Caterina Fumagalli
Massimo BarberisMassimo Barberis
Massimo Barberis
Breast tumor heterogeneity is a major challenge in the clinical management of breast cancer patients. Both inter-tumor and intra-tumor heterogeneity imply that each breast cancer (BC) could have different prognosis and would benefit from specific therapy. Breast cancer is a dynamic entity, changing during tumor progression and metastatization and this poses fundamental issues to the feasibility of a personalized medicine approach. The most effective therapeutic strategy for patients with recurrent disease should be assessed evaluating biopsies obtained from metastatic sites. Furthermore, the tumor progression and the treatment response should be strictly followed and radiogenomics and liquid biopsy might be valuable tools to assess BC heterogeneity in a non-invasive way.

29 April 2015 in Neuroendocrinology
Verified
Journal Article
Open access
PDF file
AKAnna Koumarianou
Anna Koumarianou
Gregory KaltsasGregory Kaltsas
Gregory Kaltsas
MKMatthew H. Kulke
Matthew H. Kulke
KOKjell Oberg
Kjell Oberg
JSJonathan R. Strosberg
Jonathan R. Strosberg
NFNicola Fazio
Nicola Fazio
Alkylating agents, such as streptozocin and dacarbazine, have been reported as active in neuroendocrine neoplasms (NENs). Temozolomide (TMZ) is an oral, potentially less toxic derivative of dacarbazine, which has shown activity both as a single agent and in combination with other drugs. Nevertheless, its role in NENs has not been well defined. Several retrospective and prospective phase I-II studies have been published describing its use in a variety of NENs. In a retrospective series, the combination of capecitabine and TMZ was reported to be associated with a particularly high tumour response in pancreatic NENs as a first-line treatment. Although in NENs, determination of the O6-methylguanine-DNA methyltransferase (MGMT) status has been suggested as a predictive biomarker of response, its role still remains investigational, awaiting validation along with the establishment of the optimal detection method. Metronomic schedules have been reported to potentially overcome MGMT-related drug resistance. Toxicity is manageable if well monitored. We reviewed the literature regarding pharmacological and clinical aspects of TMZ, focusing on specific settings of NENs, different schedules, toxicity and safety profiles, and potential predictive biomarkers of response.

1 January 2020 in ESMO Open
Verified
Journal Article
Open access
PDF file
APANTONIO PASSARO
ANTONIO PASSARO
UMUmberto Malapelle
Umberto Malapelle
MRMarzia Del Re
Marzia Del Re
IAIlaria Attili
Ilaria Attili
ARAlessandro Russo
Alessandro Russo
Christian RolfoChristian Rolfo
Christian Rolfo
The advances in understanding the inherited biological mechanisms of non-small cell lung cancer harbouring epidermal growth factor receptor (EGFR) mutations led to a significant improvement in the outcomes of patients treated with EGFR tyrosine kinase inhibitors. Despite these clinically impressive results, clinical results are not always uniform, suggesting the need for deepening the molecular heterogeneity of this molecularly defined subgroup of patients beyond the clinical and biological surface. The availability of tissue and blood-based tumour genotyping allows us to improve the understanding of molecular and genetic intratumor heterogeneity, driving the measurement of clonal evaluation in patients with lung cancer carrying EGFR mutations. Genetic diversification, clonal expansion and selection are highly variable patterns of genetic diversity, resulting in different biological entities, also a prerequisite for Darwinian selection and therapeutic failure. Such emerging pieces of evidence on the genetic diversity, including adaptive and immunomodulated aspects, provide further evidence for the role of the tumour microenvironment (TME) in drug-resistance and immune-mediated mechanisms. Matching in daily clinical practice, the detailed genomic profile of lung cancer disease and tracking the clonal evolution could be the way to individualise the further target treatments in EGFR-positive disease. Characterising the tumour and immune microenvironment during the time of the cancer evaluation could be the way forward for the qualitative leap needed from bench to bedside. Such a daring approach, aiming at personalising treatment selection in order to exploit the TME properties and weaken tumour adaptivity, should be integrated into clinical trial design to optimise patient outcome.